| Success story

Alentis Therapeutics

Developing breakthrough treatments for fibrotic disease

Alentis is a Swiss-French biotech company, spun out of the University of Strasbourg. Its develops breakthrough treatments for fibrotic diseases and associated cancers, initially advanced liver fibrosis and hepatocellular carcinoma, based on previously undiscovered functional role of Claudin-1. Alentis further has a platform technology for the discovery and validation of novel targets in liver disease.

Alentis was founded in 2018 and was financed, incubated and built in close collaboration between Prof. Thomas Baumert, the scientific founder of Alentis and the team of BaseLaunch. The work culminated in Alentis raising a Series A in early 2019, co-led by Pureos Bioventures, BioMedPartners, and BPI, and subsequent B and C rounds in 2021 and 2023, respectively. Bringing the total raise to USD 185M.

There is no other incubator like BaseLaunch and Alentis would not exist without it. BaseLaunch has backed us in critical times and was invaluable on all aspects of getting the company launched, being it on licensing our IP, helping assemble the initial team or supporting our series A financing. To this day, from time to time we still make use of their support and incredible network.

Thomas BaumertFounder and Executive BoD

Application cycle is now open!

The next deadline is 4 September 2024